Hyperlipidemia Drugs Market

Global Hyperlipidemia Drugs Market Size, Trends & Analysis - Forecasts to 2028 By Drug Class (Statins, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, PCSK9 Inhibitors, Combination, and Miscellaneous), and By Region (North America, Asia Pacific, Central & South America, Europe, and Middle East and Africa), Competitive Landscape, Company Market Share Analysis, and Competitor Analysis

Category Healthcare

Format

This report was recently updated on November 15 2024 with the latest and most recent market numbers

Global Hyperlipidemia Drugs Market Size

The global hyperlipidemia drugs market is expected to grow at a CAGR of 2.7% from 2023 to 2028. A medical disorder known as hyperlipidemia is characterized by high amounts of lipids (fats), such as triglycerides and cholesterol, in the blood. It poses a severe risk for heart attacks, strokes, and other cardiovascular disorders. Due to rising hyperlipidemia prevalence, changing lifestyles, and aging populations, the global market for hyperlipidemia drugs has been growing steadily.

The key factors driving the market growth are increasing incidence of chronic diseases such as diabetes, cancer etc, unhealthy lifestyle choices, and growing geriatric population.

Changing lifestyles, inconsistent weight growth, unhealthy meals, and smoking and drinking are all rising. Hyperlipidemia has increased due to the adoption of poor diets, sedentary lifestyles, and a lack of physical activity. These lifestyle variables have increased the need for medications to control cholesterol levels. One of the cardiovascular diseases (CVD) for which hyperlipidemia is a significant risk factor is heart attacks and strokes. Given the prevalence of CVD worldwide, controlling hyperlipidemia is prioritized to lower the overall risk of developing CVD. Such health issues also arise with age.

Early diagnosis and more regular tests have resulted in a greater understanding of the consequences of untreated hyperlipidemia among patients and healthcare professionals. As a result, more people are receiving a hyperlipidemia diagnosis, increasing the need for lipid-lowering medications. The pharmaceutical industry's ongoing research and development has created new, more potent lipid-lowering drugs. These developments have increased the number of available treatments and enhanced patient outcomes.

global hyperlipidemia drugs market

Global Hyperlipidemia Drugs Market: By Drug Class

Based on drug class method, the market is segmented into statins, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, PCSK9 inhibitors, combination and miscellaneous.

As per the analysis, statin segment is expected to hold the largest share of the market and to exhibit highest growth rate during the forecast period. It functions by preventing an enzyme involved in the creation of cholesterol, which lowers blood cholesterol levels. Commonly used statin drugs include atorvastatin, simvastatin, rosuvastatin, and lovastatin. Statins are preferred due to its advantages, such as better endothelial function, increased atherosclerotic plaque stability, and decreased oxidative stress-induced cellular damage and inflammation, thereby driving the segment growth.

PCSK9 inhibitors is expected to have the second highest rate of growth in the forecast period. PCSK9 inhibitors are a relatively new family of medications that inhibit the PCSK9 enzyme, which is involved in cholesterol metabolism. These medications increase the number of LDL receptors in the liver by decreasing PCSK9, which increases the removal of LDL cholesterol from the blood. As PCSK9 inhibitors, monoclonal antibodies like evolocumab and alirocumab are used to treat hyperlipidemia.

The global hyperlipidemia drugs market has seen growth and innovation in these drug classes over the years, with new drugs continually being developed and approved.

asia pacific hyperlipidemia drugs market

Global Hyperlipidemia Drugs Market: By Region

North American is analyzed to be the largest region in the global hyperlipidemia drugs market during the forecast period. Due to its huge population, high frequency of hyperlipidemia, and prevalence of cardiovascular illnesses, North America has a sizable market for hyperlipidemia medications. A well-developed healthcare system, rising awareness of hyperlipidemia, and favourable reimbursement policies are some of the market-driving factors.

Asia Pacific is expected to be the fastest growing region across the global hyperlipidemia drugs market. In nations, such as China, Japan, India, and South Korea, the market growth is driven by the ageing population and increase in awareness of cardiac disease.

European nations with high prevalence of hyperlipidemia include the United Kingdom, Germany, France, Italy, and Spain. These nations also have established healthcare systems. This region has a sizable market for medications to treat hyperlipidemia, which is fuelled by increased ageing population, unhealthy eating patterns, sedentary lifestyle, and growing cardiovascular health awareness. Hyperlipidemia has affected a large number of Middle Eastern nations. Due to population increase, urbanisation, and lifestyle changes in these areas, the market for lipid-lowering medications is increasing. Government spending on enhancing healthcare facilities and expanding access to treatments is another factor driving market growth in this region. The hyperlipidemia drugs market in African countries is relatively smaller, but it is growing due to increasing healthcare investment and awareness of chronic diseases like hyperlipidemia.

Global Hyperlipidemia Drugs Market Share and Competitor Analysis

The key players operating in the market are Amgen Inc., AstraZeneca PLC, Daiichi Sankyo Company Limited, Eli Lilly and Company, Esperion Therapeutics Inc., Immuron Limited, Ionis Pharmaceuticals Inc., Merck & Co. Inc., Pfizer Inc., and Sanofi S.A. among others.

Please note: This is not an exhaustive list of companies profiled in the report.

1 STRATEGIC INSIGHTS ON NEW REVENUE POCKETS

1.1 Strategic Opportunity & Attractiveness Analysis

1.1.1 Hot Revenue Pockets

1.1.2 Market Attractiveness Score

1.1.3 Revenue Impacting Opportunity

1.1.4 High Growing Region/Country

1.1.5 Competitor Analysis

1.1.6 Consumer Analysis

1.2 Global Market Estimates' View

1.3 Strategic Insights across Business Functions

1.3.1 For Chief Executive Officers

1.3.2 For Chief Marketing Officers

1.3.3 For Chief Strategy Officers

1.4 Evaluate the Potential of your Existing Business Lines vs. New Lines to Enter Into

2 TECHNOLOGICAL TRENDS

2.1 Technological Adoption Rate

2.2 Current Trend Impact Analysis

2.3 Future Trend Impact Analysis

2.4 Data Metrics

3 GLOBAL MARKET OUTLOOK

3.1 Market Pyramid Analysis

3.1.1 Introduction

3.1.2 Adjacent Market Opportunities

3.1.3 Ancillary Market Opportunities

3.2 Demand Side Analysis

3.2.1 Market Drivers: Impact Analysis

3.2.2 Market Restraints: Impact Analysis

3.2.3 Market Opportunities: Impact Analysis

3.2.4 Market Challenges: Impact Analysis

3.3 Supply Side Analysis

3.3.1 Porter’s Five Forces Analysis

3.3.1.1 Threat of New Entrants

3.3.1.2 Threat of New Substitutes

3.3.1.3 Bargaining Power of Suppliers

3.3.1.4 Bargaining Power of Buyers

3.3.1.5 Intensity of Competitive Rivalry

3.3.2 SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)

3.3.2.1 Political Landscape

3.3.2.2 Economic Landscape

3.3.2.3 Social Landscape

3.3.2.4 Technology Landscape

3.3.3 Value Chain Analysis

3.3.4 Trend Analysis

3.3.5 Gap Analysis

3.3.6 Cost Analysis

4 GLOBAL HYPERLIPIDEMIA DRUG MARKET, BY DRUG CLASS

4.1 Introduction

4.2 Hyperlipidemia Drug Market: Drug Class Scope Key Takeaways

4.3 Revenue Growth Analysis, 2022 & 2028

4.4 Statins

4.4.1 Statins Market Estimates and Forecast, 2020-2028 (USD Million)

4.5 Bile Acid Sequestrants

4.5.1 Bile Acid Sequestrants Market Estimates and Forecast, 2020-2028 (USD Million)

4.6 Cholesterol Absorption Inhibitors

4.6.1 Cholesterol Absorption Inhibitors Market Estimates and Forecast, 2020-2028 (USD Million)

4.7 Fibric Acid Derivatives

4.7.1 Fibric Acid Derivatives Market Estimates and Forecast, 2020-2028 (USD Million)

4.8 PCSK9 Inhibitors

4.8.1 PCSK9 Inhibitors Market Estimates and Forecast, 2020-2028 (USD Million)

4.9 Combination

4.9.1 Combination Market Estimates and Forecast, 2020-2028 (USD Million)

4.10 Miscellaneous

4.10.1 Miscellaneous Market Estimates and Forecast, 2020-2028 (USD Million)

5 GLOBAL HYPERLIPIDEMIA DRUG MARKET, BY REGION

5.1 Introduction

5.2 North America Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.2.1 By Drug Class

5.2.2 By Country

5.2.3.1 U.S. Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.2.3.1.1 By Drug Class

5.2.3.2 Canada Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.2.3.2.1 By Drug Class

5.2.3.3 Mexico Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.2.3.3.1 By Drug Class

5.3 Europe Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.3.1 By Drug Class

5.3.2 By Country

5.3.3.1 Germany Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.3.3.1.1 By Drug Class

5.3.3.2 U.K. Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.3.3.2.1 By Drug Class

5.3.3.3 France Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.3.3.3.1 By Drug Class

5.3.3.4 Italy Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.3.3.4.1 By Drug Class

5.3.3.5 Spain Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.3.3.5.1 By Drug Class

5.3.3.6 Netherlands Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.3.3.6.1 By Drug Class

5.3.3.7 Rest of Europe Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.3.3.6.1 By Drug Class

5.4 Asia Pacific Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.4.1 By Drug Class

5.4.2 By Country

5.4.3.1 China Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.4.3.1.1 By Drug Class

5.4.3.2 Japan Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.4.3.2.1 By Drug Class

5.4.3.3 India Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.4.3.3.1 By Drug Class

5.4.3.4 South Korea Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.4.3.4.1 By Drug Class

5.4.3.5 Singapore Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.4.3.5.1 By Drug Class

6.4.3.6 Malaysia Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.4.3.6.1 By Drug Class

5.4.3.7 Thailand Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.4.3.6.1 By Drug Class

5.4.3.8 Indonesia Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.4.3.7.1 By Drug Class

5.4.3.9 Vietnam Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.4.3.8.1 By Drug Class

5.4.3.10 Taiwan Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.4.3.10.1 By Drug Class

5.4.3.11 Rest of Asia Pacific Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.4.3.11.1 By Drug Class

5.5 Middle East and Africa Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.5.1 By Drug Class

5.5.2 By Country

5.5.3.1 Saudi Arabia Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.5.3.1.1 By Drug Class

5.5.3.2 U.A.E. Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.5.3.2.1 By Drug Class

5.5.3.3 Israel Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.5.3.3.1 By Drug Class

5.5.3.4 South Africa Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.5.3.4.1 By Drug Class

5.5.3.5 Rest of Middle East and Africa Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.5.3.5.1 By Drug Class

5.6 Central & South America Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.6.1 By Drug Class

5.6.2 By Country

5.6.3.1 Brazil Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.6.3.1.1 By Drug Class

5.6.3.2 Argentina Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.6.3.2.1 By Drug Class

5.6.3.3 Chile Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.6.3.3.1 By Drug Class

5.6.3.3 Rest of Central & South America Hyperlipidemia Drug Market Estimates and Forecast, 2020-2028 (USD Million)

5.6.3.3.1 By Drug Class

6 COMPETITIVE LANDCAPE

6.1 Company Market Share Analysis

6.2 Four Quadrant Positioning Matrix

6.2.1 Market Leaders

6.2.2 Market Visionaries

6.2.3 Market Challengers

6.2.4 Niche Market Players

6.3.4 Rest of the World

6.4 Company Profiles

6.4.1 Amgen Inc.

6.4.1.1 Business Description & Financial Analysis

6.4.1.2 SWOT Analysis

6.4.1.3 Products & Services Offered

6.4.1.4 Strategic Alliances between Business Partners

6.4.2 AstraZeneca PLC

6.4.2.1 Business Description & Financial Analysis

6.4.2.2 SWOT Analysis

6.4.2.3 Products & Services Offered

6.4.2.4 Strategic Alliances between Business Partners

6.4.3 Daiichi Sankyo Company Limited

6.4.3.1 Business Description & Financial Analysis

6.4.3.2 SWOT Analysis

6.4.3.3 Products & Services Offered

6.4.3.4 Strategic Alliances between Business Partners

6.4.4 Eli Lilly and Company

6.4.4.1 Business Description & Financial Analysis

6.4.4.2 SWOT Analysis

6.4.4.3 Products & Services Offered

6.4.4.4 Strategic Alliances between Business Partners

6.4.5 Esperion Therapeutics Inc.

6.4.5.1 Business Description & Financial Analysis

6.4.5.2 SWOT Analysis

6.4.5.3 Products & Services Offered

6.4.5.4 Strategic Alliances between Business Partners

6.4.6 Immuron Limited

6.4.6.1 Business Description & Financial Analysis

6.4.6.2 SWOT Analysis

6.4.6.3 Products & Services Offered

6.4.6.4 Strategic Alliances between Business Partners

6.4.7 Ionis Pharmaceuticals Inc.

6.4.7.1 Business Description & Financial Analysis

6.4.7.2 SWOT Analysis

6.4.7.3 Products & Services Offered

6.4.7.4 Strategic Alliances between Business Partners

6.4.8 Merck & Co. Inc.

6.4.8.1 Business Description & Financial Analysis

6.4.8.2 SWOT Analysis

6.4.8.3 Products & Services Offered

6.4.8.4 Strategic Alliances between Business Partners

6.4.9 Pfizer Inc.

6.4.9.1 Business Description & Financial Analysis

6.4.9.2 SWOT Analysis

6.4.9.3 Products & Services Offered

6.4.9.4 Strategic Alliances between Business Partners

6.4.10 Sanofi S.A.

6.4.10.1 Business Description & Financial Analysis

6.4.10.2 SWOT Analysis

6.4.10.3 Products & Services Offered

6.4.10.4 Strategic Alliances between Business Partners

6.4.11 Other Companies

6.4.11.1 Business Description & Financial Analysis

6.4.11.2 SWOT Analysis

6.4.11.3 Products & Services Offered

6.4.11.4 Strategic Alliances between Business Partners

7 RESEARCH METHODOLOGY

7.1 Market Introduction

7.1.1 Market Definition

7.1.2 Market Scope & Segmentation

7.2 Information Procurement

7.2.1 Secondary Research

7.2.1.1 Purchased Databases

7.2.1.2 GMEs Internal Data Repository

7.2.1.3 Secondary Resources & Third Party Perspectives

7.2.1.4 Company Information Sources

7.2.2 Primary Research

7.2.2.1 Various Types of Respondents for Primary Interviews

7.2.2.2 Number of Interviews Conducted throughout the Research Process

7.2.2.3 Primary Stakeholders

7.2.2.4 Discussion Guide for Primary Participants

7.2.3 Expert Panels

7.2.3.1 Expert Panels Across 30+ Industry

7.2.4 Paid Local Experts

7.2.4.1 Paid Local Experts Across 30+ Industry Across each Region

7.3 Market Estimation

7.3.1 Top-Down Approach

7.3.1.1 Macro-Economic Indicators Considered

7.3.1.2 Micro-Economic Indicators Considered

7.3.2 Bottom Up Approach

7.3.2.1 Company Share Analysis Approach

7.3.2.2 Estimation of Potential Product Sales

7.4 Data Triangulation

7.4.1 Data Collection

7.4.2 Time Series, Cross Sectional & Panel Data Analysis

7.4.3 Cluster Analysis

7.5 Analysis and Output

7.5.1 Inhouse AI Based Real Time Analytics Tool

7.5.2 Output From Desk & Primary Research

7.6 Research Assumptions & Limitations

7.6.1 Research Assumptions

7.6.2 Research Limitations

LIST OF TABLES

1 Global Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

2 Statins Market, By Region, 2020-2028 (USD Mllion)

3 Bile Acid Sequestrants Market, By Region, 2020-2028 (USD Mllion)

4 Cholesterol Absorption Inhibitors Market, By Region, 2020-2028 (USD Mllion)

5 Fibric Acid Derivatives Market, By Region, 2020-2028 (USD Mllion)

6 PCSK9 Inhibitors Market, By Region, 2020-2028 (USD Mllion)

7 Combination Market, By Region, 2020-2028 (USD Mllion)

8 Miscellaneous Market, By Region, 2020-2028 (USD Mllion)

9 Regional Analysis, 2020-2028 (USD Mllion)

10 North America Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

11 U.S. Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

12 Canada Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

13 Mexico Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

14 Europe Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

15 Germany Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

16 U.K. Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

17 France Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

18 Italy Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

19 Spain Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

20 Netherlands Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

21 Rest Of Europe Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

22 Asia Pacific Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

23 China Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

24 Japan Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

25 India Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

26 South Korea Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

27 Singapore Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

28 Thailand Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

29 Malaysia Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

30 Indonesia Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

31 Vietnam Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

32 Taiwan Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

33 Rest of APAC Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

34 Middle East and Africa Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

35 Saudi Arabia Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

36 UAE Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

37 Israel Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

38 South Africa Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

39 Rest Of Middle East and Africa Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

40 Central & South America Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

41 Brazil Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

42 Chile Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

43 Argentina Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

44 Rest Of Central & South America Hyperlipidemia Drug Market, By Drug Class, 2020-2028 (USD Mllion)

45 Amgen Inc.: Products & Services Offering

46 AstraZeneca PLC: Products & Services Offering

47 Daiichi Sankyo Company Limited: Products & Services Offering

48 Eli Lilly and Company: Products & Services Offering

49 Esperion Therapeutics Inc.: Products & Services Offering

50 IMMURON LIMITED: Products & Services Offering

51 Ionis Pharmaceuticals Inc. : Products & Services Offering

52 Merck & Co. Inc.: Products & Services Offering

53 Pfizer Inc.: Products & Services Offering

54 Sanofi S.A.: Products & Services Offering

55 Other Companies: Products & Services Offering

LIST OF FIGURES

1 Global Hyperlipidemia Drug Market Overview

2 Global Hyperlipidemia Drug Market Value From 2020-2028 (USD Mllion)

3 Global Hyperlipidemia Drug Market Share, By Drug Class (2022)

4 Global Hyperlipidemia Drug Market, By Region (Asia Pacific Market)

5 Technological Trends In Global Hyperlipidemia Drug Market

6 Four Quadrant Competitor Positioning Matrix

7 Impact Of Macro & Micro Indicators On The Market

8 Impact Of Key Drivers On The Global Hyperlipidemia Drug Market

9 Impact Of Challenges On The Global Hyperlipidemia Drug Market

10 Porter’s Five Forces Analysis

11 Global Hyperlipidemia Drug Market: By Drug Class Scope Key Takeaways

12 Global Hyperlipidemia Drug Market, By Drug Class Segment: Revenue Growth Analysis

13 Statins Market, By Region, 2020-2028 (USD Mllion)

14 Bile Acid Sequestrants Market, By Region, 2020-2028 (USD Mllion)

15 Cholesterol Absorption Inhibitors Market, By Region, 2020-2028 (USD Mllion)

16 Fibric Acid Derivatives Market, By Region, 2020-2028 (USD Mllion)

17 PCSK9 Inhibitors Market, By Region, 2020-2028 (USD Mllion)

18 Combination Market, By Region, 2020-2028 (USD Mllion)

19 Miscellaneous Market, By Region, 2020-2028 (USD Mllion)

20 Regional Segment: Revenue Growth Analysis

21 Global Hyperlipidemia Drug Market: Regional Analysis

22 North America Hyperlipidemia Drug Market Overview

23 North America Hyperlipidemia Drug Market, By Drug Class

24 North America Hyperlipidemia Drug Market, By Country

25 U.S. Hyperlipidemia Drug Market, By Drug Class

26 Canada Hyperlipidemia Drug Market, By Drug Class

27 Mexico Hyperlipidemia Drug Market, By Drug Class

28 Four Quadrant Positioning Matrix

29 Company Market Share Analysis

30 Amgen Inc.: Company Snapshot

31 Amgen Inc.: SWOT Analysis

32 Amgen Inc.: Geographic Presence

33 AstraZeneca PLC: Company Snapshot

34 AstraZeneca PLC: SWOT Analysis

35 AstraZeneca PLC: Geographic Presence

36 Daiichi Sankyo Company Limited: Company Snapshot

37 Daiichi Sankyo Company Limited: SWOT Analysis

38 Daiichi Sankyo Company Limited: Geographic Presence

39 Eli Lilly and Company: Company Snapshot

40 Eli Lilly and Company: Swot Analysis

41 Eli Lilly and Company: Geographic Presence

42 Esperion Therapeutics Inc.: Company Snapshot

43 Esperion Therapeutics Inc.: SWOT Analysis

44 Esperion Therapeutics Inc.: Geographic Presence

45 Immuron Limited: Company Snapshot

46 Immuron Limited: SWOT Analysis

47 Immuron Limited: Geographic Presence

48 Ionis Pharmaceuticals Inc. : Company Snapshot

49 Ionis Pharmaceuticals Inc. : SWOT Analysis

50 Ionis Pharmaceuticals Inc. : Geographic Presence

51 Merck & Co. Inc.: Company Snapshot

52 Merck & Co. Inc.: SWOT Analysis

53 Merck & Co. Inc.: Geographic Presence

54 Pfizer Inc..: Company Snapshot

55 Pfizer Inc..: SWOT Analysis

56 Pfizer Inc..: Geographic Presence

57 Sanofi S.A.: Company Snapshot

58 Sanofi S.A.: SWOT Analysis

59 Sanofi S.A.: Geographic Presence

60 Other Companies: Company Snapshot

61 Other Companies: SWOT Analysis

62 Other Companies: Geographic Presence

The Global Hyperlipidemia Drugs Market has been studied from the year 2019 till 2028. However, the CAGR provided in the report is from the year 2023 to 2028. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.

The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Hyperlipidemia Drugs Market.

The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.

Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.

We value your investment and offer free customization with every report to fulfil your exact research needs.

This website is secure and your personal details are safe. Privacy

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

What is the projected market size of the global hyperlipidemia drugs market?

The global hyperlipidemia drugs market is expected to grow at a CAGR of 2.7% from 2023 to 2028.

Who are the major vendors in the global hyperlipidemia drugs market?

What are the opportunities prevailing in the global hyperlipidemia drugs market?

The global hyperlipidemia drugs market offers opportunities driven by increase in the occurrence of chronic diseases such as diabetes, cancer etc, unhealthy lifestyle choices as well as growing geriatric population.

What are the major drivers for the global hyperlipidemia drugs market growth?

The global market growth is driven by factors such as increase in the occurrence of chronic diseases such as diabetes, cancer etc, unhealthy lifestyle choices, and growing geriatric population.